Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria
The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters, has caused a public health crisis of global dimensions. These organisms cause serious infections in hospitalized patients, and are associated with increased mortality. Cros...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2012-05, Vol.18 (5), p.439-448 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 448 |
|---|---|
| container_issue | 5 |
| container_start_page | 439 |
| container_title | Clinical microbiology and infection |
| container_volume | 18 |
| creator | Akova, M. Daikos, G.L. Tzouvelekis, L. Carmeli, Y. |
| description | The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters, has caused a public health crisis of global dimensions. These organisms cause serious infections in hospitalized patients, and are associated with increased mortality. Cross-transmission is common, and outbreaks may occur in healthcare facilities where the infection control practices are inadequate. CPGNs exhibit extensive drug-resistant phenotypes, complicate therapy, and limit treatment options. Systematic data on therapy are limited. However, regimens combining two or more active agents seem to be more efficacious than monotherapy in carbapenemase-producing Klebsiella pneumoniae infections. Strict infection control measures, including active surveillance for timely detection of colonized patients, separation of carriers from non-carriers, and contact precautions, are of utmost importance, and may be the only effective way of preventing the introduction and transmission of these bacteria in healthcare settings. |
| doi_str_mv | 10.1111/j.1469-0691.2012.03823.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1028023163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X14625477</els_id><sourcerecordid>1002567886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5393-4092900af191bff7bcd3c4a5f841a003e697cbe8d742d59c2979cc0d82c358b43</originalsourceid><addsrcrecordid>eNqNkU9v1DAQxSNERUvhK6BIXLgk9b8k9oEDrKCttKgXkLhZzniyeJU4i51st98ep9v20Av1xSPN770ZzcuynJKSpnexLamoVUFqRUtGKCsJl4yXh1fZ2VPjdaqpkkUj-O_T7G2MW0II41y8yU4Zq0iTjM6y4dpPGPboJzd60-dxCmbCjcOYG29zmENIvRx65x2kPh52GBx6wPzWTX9yMKE1O_Q4mIjFLox2Buc3-WUwQ-FxYya3x7w1kKY48y476Uwf8f3Df579-v7t5-qqWN9cXq--rAuouOKFIIopQkxHFW27rmnBchCm6qSghhCOtWqgRWkbwWylgKlGARArGfBKtoKfZ5-OvmmhvzPGSQ8uAva98TjOUVPCZLoFrfkLUMKqupGyTujHZ-h2nEO6WqIqUSnBCKkSJY8UhDHGgJ3eBTeYcJes9JKe3uolJL2EpJf09H16-pCkHx4GzO2A9kn4GFcCPh-BW9fj3YuN9Wr9Y6mS_utRj-n4e4dBR7gP07qAMGk7uv9v-Q-I3L5e</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545942005</pqid></control><display><type>article</type><title>Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Akova, M. ; Daikos, G.L. ; Tzouvelekis, L. ; Carmeli, Y.</creator><creatorcontrib>Akova, M. ; Daikos, G.L. ; Tzouvelekis, L. ; Carmeli, Y.</creatorcontrib><description>The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters, has caused a public health crisis of global dimensions. These organisms cause serious infections in hospitalized patients, and are associated with increased mortality. Cross-transmission is common, and outbreaks may occur in healthcare facilities where the infection control practices are inadequate. CPGNs exhibit extensive drug-resistant phenotypes, complicate therapy, and limit treatment options. Systematic data on therapy are limited. However, regimens combining two or more active agents seem to be more efficacious than monotherapy in carbapenemase-producing Klebsiella pneumoniae infections. Strict infection control measures, including active surveillance for timely detection of colonized patients, separation of carriers from non-carriers, and contact precautions, are of utmost importance, and may be the only effective way of preventing the introduction and transmission of these bacteria in healthcare settings.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1111/j.1469-0691.2012.03823.x</identifier><identifier>PMID: 22507111</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Bacterial Proteins - biosynthesis ; Bacterial Proteins - genetics ; beta-Lactamases - biosynthesis ; beta-Lactamases - genetics ; Carbapenemase ; Carbapenems - pharmacology ; Carbapenems - therapeutic use ; Carrier State - drug therapy ; Carrier State - microbiology ; Carrier State - prevention & control ; Cross Infection - drug therapy ; Cross Infection - microbiology ; Cross Infection - prevention & control ; Data processing ; Disease Outbreaks ; Disease transmission ; Drug resistance ; Gram-negative bacteria ; Gram-Negative Bacteria - drug effects ; Gram-Negative Bacteria - enzymology ; Gram-Negative Bacteria - genetics ; Gram-Negative Bacterial Infections - drug therapy ; Gram-Negative Bacterial Infections - microbiology ; Gram-Negative Bacterial Infections - prevention & control ; Gram-negatives ; Health facilities ; Humans ; Infection ; infection control ; Infection Control - methods ; Klebsiella pneumoniae ; Mortality ; Public health ; Risk Factors ; treatment</subject><ispartof>Clinical microbiology and infection, 2012-05, Vol.18 (5), p.439-448</ispartof><rights>2012 European Society of Clinical Infectious Diseases</rights><rights>2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5393-4092900af191bff7bcd3c4a5f841a003e697cbe8d742d59c2979cc0d82c358b43</citedby><cites>FETCH-LOGICAL-c5393-4092900af191bff7bcd3c4a5f841a003e697cbe8d742d59c2979cc0d82c358b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1469-0691.2012.03823.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1469-0691.2012.03823.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22507111$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akova, M.</creatorcontrib><creatorcontrib>Daikos, G.L.</creatorcontrib><creatorcontrib>Tzouvelekis, L.</creatorcontrib><creatorcontrib>Carmeli, Y.</creatorcontrib><title>Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters, has caused a public health crisis of global dimensions. These organisms cause serious infections in hospitalized patients, and are associated with increased mortality. Cross-transmission is common, and outbreaks may occur in healthcare facilities where the infection control practices are inadequate. CPGNs exhibit extensive drug-resistant phenotypes, complicate therapy, and limit treatment options. Systematic data on therapy are limited. However, regimens combining two or more active agents seem to be more efficacious than monotherapy in carbapenemase-producing Klebsiella pneumoniae infections. Strict infection control measures, including active surveillance for timely detection of colonized patients, separation of carriers from non-carriers, and contact precautions, are of utmost importance, and may be the only effective way of preventing the introduction and transmission of these bacteria in healthcare settings.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacterial Proteins - biosynthesis</subject><subject>Bacterial Proteins - genetics</subject><subject>beta-Lactamases - biosynthesis</subject><subject>beta-Lactamases - genetics</subject><subject>Carbapenemase</subject><subject>Carbapenems - pharmacology</subject><subject>Carbapenems - therapeutic use</subject><subject>Carrier State - drug therapy</subject><subject>Carrier State - microbiology</subject><subject>Carrier State - prevention & control</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - microbiology</subject><subject>Cross Infection - prevention & control</subject><subject>Data processing</subject><subject>Disease Outbreaks</subject><subject>Disease transmission</subject><subject>Drug resistance</subject><subject>Gram-negative bacteria</subject><subject>Gram-Negative Bacteria - drug effects</subject><subject>Gram-Negative Bacteria - enzymology</subject><subject>Gram-Negative Bacteria - genetics</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Gram-Negative Bacterial Infections - microbiology</subject><subject>Gram-Negative Bacterial Infections - prevention & control</subject><subject>Gram-negatives</subject><subject>Health facilities</subject><subject>Humans</subject><subject>Infection</subject><subject>infection control</subject><subject>Infection Control - methods</subject><subject>Klebsiella pneumoniae</subject><subject>Mortality</subject><subject>Public health</subject><subject>Risk Factors</subject><subject>treatment</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9v1DAQxSNERUvhK6BIXLgk9b8k9oEDrKCttKgXkLhZzniyeJU4i51st98ep9v20Av1xSPN770ZzcuynJKSpnexLamoVUFqRUtGKCsJl4yXh1fZ2VPjdaqpkkUj-O_T7G2MW0II41y8yU4Zq0iTjM6y4dpPGPboJzd60-dxCmbCjcOYG29zmENIvRx65x2kPh52GBx6wPzWTX9yMKE1O_Q4mIjFLox2Buc3-WUwQ-FxYya3x7w1kKY48y476Uwf8f3Df579-v7t5-qqWN9cXq--rAuouOKFIIopQkxHFW27rmnBchCm6qSghhCOtWqgRWkbwWylgKlGARArGfBKtoKfZ5-OvmmhvzPGSQ8uAva98TjOUVPCZLoFrfkLUMKqupGyTujHZ-h2nEO6WqIqUSnBCKkSJY8UhDHGgJ3eBTeYcJes9JKe3uolJL2EpJf09H16-pCkHx4GzO2A9kn4GFcCPh-BW9fj3YuN9Wr9Y6mS_utRj-n4e4dBR7gP07qAMGk7uv9v-Q-I3L5e</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>Akova, M.</creator><creator>Daikos, G.L.</creator><creator>Tzouvelekis, L.</creator><creator>Carmeli, Y.</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201205</creationdate><title>Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria</title><author>Akova, M. ; Daikos, G.L. ; Tzouvelekis, L. ; Carmeli, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5393-4092900af191bff7bcd3c4a5f841a003e697cbe8d742d59c2979cc0d82c358b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacterial Proteins - biosynthesis</topic><topic>Bacterial Proteins - genetics</topic><topic>beta-Lactamases - biosynthesis</topic><topic>beta-Lactamases - genetics</topic><topic>Carbapenemase</topic><topic>Carbapenems - pharmacology</topic><topic>Carbapenems - therapeutic use</topic><topic>Carrier State - drug therapy</topic><topic>Carrier State - microbiology</topic><topic>Carrier State - prevention & control</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - microbiology</topic><topic>Cross Infection - prevention & control</topic><topic>Data processing</topic><topic>Disease Outbreaks</topic><topic>Disease transmission</topic><topic>Drug resistance</topic><topic>Gram-negative bacteria</topic><topic>Gram-Negative Bacteria - drug effects</topic><topic>Gram-Negative Bacteria - enzymology</topic><topic>Gram-Negative Bacteria - genetics</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Gram-Negative Bacterial Infections - microbiology</topic><topic>Gram-Negative Bacterial Infections - prevention & control</topic><topic>Gram-negatives</topic><topic>Health facilities</topic><topic>Humans</topic><topic>Infection</topic><topic>infection control</topic><topic>Infection Control - methods</topic><topic>Klebsiella pneumoniae</topic><topic>Mortality</topic><topic>Public health</topic><topic>Risk Factors</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akova, M.</creatorcontrib><creatorcontrib>Daikos, G.L.</creatorcontrib><creatorcontrib>Tzouvelekis, L.</creatorcontrib><creatorcontrib>Carmeli, Y.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akova, M.</au><au>Daikos, G.L.</au><au>Tzouvelekis, L.</au><au>Carmeli, Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2012-05</date><risdate>2012</risdate><volume>18</volume><issue>5</issue><spage>439</spage><epage>448</epage><pages>439-448</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>The wide dissemination of carbapenemase-producing Gram-negatives (CPGNs), including enterobacterial species and non-fermenters, has caused a public health crisis of global dimensions. These organisms cause serious infections in hospitalized patients, and are associated with increased mortality. Cross-transmission is common, and outbreaks may occur in healthcare facilities where the infection control practices are inadequate. CPGNs exhibit extensive drug-resistant phenotypes, complicate therapy, and limit treatment options. Systematic data on therapy are limited. However, regimens combining two or more active agents seem to be more efficacious than monotherapy in carbapenemase-producing Klebsiella pneumoniae infections. Strict infection control measures, including active surveillance for timely detection of colonized patients, separation of carriers from non-carriers, and contact precautions, are of utmost importance, and may be the only effective way of preventing the introduction and transmission of these bacteria in healthcare settings.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>22507111</pmid><doi>10.1111/j.1469-0691.2012.03823.x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2012-05, Vol.18 (5), p.439-448 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1028023163 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacterial Proteins - biosynthesis Bacterial Proteins - genetics beta-Lactamases - biosynthesis beta-Lactamases - genetics Carbapenemase Carbapenems - pharmacology Carbapenems - therapeutic use Carrier State - drug therapy Carrier State - microbiology Carrier State - prevention & control Cross Infection - drug therapy Cross Infection - microbiology Cross Infection - prevention & control Data processing Disease Outbreaks Disease transmission Drug resistance Gram-negative bacteria Gram-Negative Bacteria - drug effects Gram-Negative Bacteria - enzymology Gram-Negative Bacteria - genetics Gram-Negative Bacterial Infections - drug therapy Gram-Negative Bacterial Infections - microbiology Gram-Negative Bacterial Infections - prevention & control Gram-negatives Health facilities Humans Infection infection control Infection Control - methods Klebsiella pneumoniae Mortality Public health Risk Factors treatment |
| title | Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T17%3A28%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interventional%20strategies%20and%20current%20clinical%20experience%20with%20carbapenemase-producing%20Gram-negative%20bacteria&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Akova,%20M.&rft.date=2012-05&rft.volume=18&rft.issue=5&rft.spage=439&rft.epage=448&rft.pages=439-448&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1111/j.1469-0691.2012.03823.x&rft_dat=%3Cproquest_cross%3E1002567886%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1545942005&rft_id=info:pmid/22507111&rft_els_id=S1198743X14625477&rfr_iscdi=true |